Here are the DEF 14A proxy statements from Summit Therapeutics Inc. (SMMT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SMMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SMMT filings page.
Summit Therapeutics Inc. is asking stockholders to approve a charter amendment that would increase authorized common shares by 1,000,000,000, from 1,000,000,000 to 2,000,000,000. The board unanimously recommends a FOR vote at the virtual special meeting on November 4, 2026; approval requires a majority of votes cast.
As of October 1, 2026, Summit had 799,726,418 common shares outstanding and 66,727,073 authorized, unreserved shares available, excluding additional shares issuable under the ATM program or private placement. The amendment is intended in part to permit conversion of Class A Preferred Stock issued in a private placement that closed October 5, 2026, for $2.0 billion in gross proceeds to Summit; 108,955,369 common shares are issuable on conversion after any applicable Hart-Scott-Rodino waiting period or extension expires or terminates and the amendment becomes effective.
Summit agreed to take all actions necessary to amend its charter by December 31, 2026. If the required increase is not effective by April 5, 2028, Summit must redeem all outstanding Class A Preferred Stock for cash at a price reflecting the then-prevailing market value of the underlying common stock. The amendment itself would not immediately dilute holders, though future issuance could reduce their voting power and percentage interests.
Summit Therapeutics Inc. is asking stockholders to vote on four proposals at its 2026 virtual annual meeting on June 10, 2026. Items include electing nine directors, ratifying PricewaterhouseCoopers LLP as auditor, an advisory “say‑on‑pay” vote on executive compensation, and an amendment adding 8,000,000 shares to the 2020 Stock Incentive Plan. As of April 15, 2026, 776,079,959 common shares were outstanding and 388,039,981 must be represented to reach a quorum.